Francisco Silva - 08 Apr 2024 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
VP of Research and Development, Director
Signature
/s/ Francisco Silva
Issuer symbol
BRTX
Transactions as of
08 Apr 2024
Net transactions value
+$10,229
Form type
4
Filing time
10 Apr 2024, 17:16:36 UTC
Previous filing
20 Mar 2024
Next filing
19 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BRTX Common Stock Purchase $538 +476 +0.32% $1.13 147,927 08 Apr 2024 Direct
transaction BRTX Common Stock Purchase $1,441 +1,232 +0.83% $1.17 149,159 08 Apr 2024 Direct
transaction BRTX Common Stock Purchase $8,250 +6,600 +4.4% $1.25 155,759 09 Apr 2024 Direct
holding BRTX Common Stock 12,136 08 Apr 2024 IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BRTX Stock Option 9 08 Apr 2024 Common Stock 9 $3000.00 Direct F1
holding BRTX Stock Option 6 08 Apr 2024 Common Stock 6 $3000.00 Direct F1
holding BRTX Stock Option 15 08 Apr 2024 Common Stock 15 $3000.00 Direct F1
holding BRTX Stock Option 20 08 Apr 2024 Common Stock 20 $3000.00 Direct F1
holding BRTX Stock Option 25 08 Apr 2024 Common Stock 25 $3000.00 Direct F1
holding BRTX Stock Option 293,479 08 Apr 2024 Common Stock 293,479 $5.08 Direct F1
holding BRTX Stock Option 42,059 08 Apr 2024 Common Stock 42,059 $5.08 Direct F2
holding BRTX Stock Option 106,762 08 Apr 2024 Common Stock 106,762 $2.91 Direct F3
holding BRTX Stock Option 394,737 08 Apr 2024 Common Stock 394,737 $1.45 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option is currently exercisable.
F2 The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 and 21,029 shares in eight nearly equal quarterly installments beginning November 4, 2022 and continuing every three months thereafter until fully vested.
F3 The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
F4 The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.